Cell therapy: Promise fulfilled?

Biologicals

Volumn 40, Issue 3, 2012, Pages 214-217

  Koh, Mickey B C ^a,b   Suck, Garnet ^a  

^a HEALTH SCIENCES AUTHORITY   (Singapore)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Bone marrow transplantation; Cancer; Cellular therapy; Immune cells; Regenerative medicine; Stem cells

Indexed keywords

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CARDIOMYOPATHY; CELL DIFFERENTIATION; CELL THERAPY; CELL TYPE; DISEASE COURSE; HEART INFARCTION; HEART MUSCLE; HUMAN; MELANOMA; NERVE CELL; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; REGENERATIVE MEDICINE; REPRODUCIBILITY; SPINAL CORD LESION; STEM CELL;

HUMANS; IMMUNOTHERAPY; NEOPLASMS; REGENERATIVE MEDICINE; STEM CELL RESEARCH; STEM CELL TRANSPLANTATION; TISSUE THERAPY;

EID: 84860608419     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2011.12.002     Document Type: Article

References (38)

1. McCarthy E.F. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 2006, 26:154-158.
2. Coley W.B. II. Contribution to the knowledge of sarcoma. Ann Surg 1891, 14:199-220.
3. Barnes D.W., Loutit J.F. Treatment of murine leukaemia with x-rays and homologous bone marrow. II. Br J Haematol 1957, 3:241-252.
4. Mathe G., Amiel J.L., Schwarzenberg L., Cattan A., Schneider M. Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res 1965, 25:1525-1531.
5. Notta F., Doulatov S., Laurenti E., Poeppl A., Jurisica I., Dick J.E. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science 2011, 333:218-221.
6. Koh M., Goh Y., Tan P., Koh L., Hwang W., Loh Y., et al. Stem cell transplantation programme at Singapore General Hospital. Bone Marrow Transplant 2008, 42(Suppl. 1). S121-S1S4.
7. Mielcarek M., Storb R. Non-myeloablative hematopoietic cell transplantation as immunotherapy for hematologic malignancies. Cancer Treat Rev 2003, 29:283-290.
8. Marsh J.C., Gupta V., Lim Z., Ho A.Y., Ireland R.M., Hayden J., et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood 2011, 118:2351-2357.
9. Costello R.T., Fauriat C., Rey J., Gastaut J.A., Olive D. Immunobiology of haematological malignant disorders: the basis for novel immunotherapy protocols. Lancet Oncol 2004, 5:47-55.
10. Rooney C.M., Heslop H.E., Brenner M.K. EBV specific CTL: a model for immune therapy. Vox Sang 1998, 74(Suppl. 2):497-498.
11. Lowdell M.W., Koh M.B. Immunotherapy of AML: future directions. J Clin Pathol 2000, 53:49-54.
12. Gottschalk S., Bollard C.M., Straathof K.C., Louis C.U., Savoldo B., Dotti G., et al. T cell therapies. Ernst Schering Found Symp Proc 2006, 69-82.
13. Suck G. Novel approaches using natural killer cells in cancer therapy. Semin Cancer Biol 2006, 16:412-418.
14. Linn Y.C., Hui K.M. Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol 2010, 2010:435745.
15. Suck G., Koh M.B. Emerging natural killer cell immunotherapies: large-scale ex vivo production of highly potent anticancer effectors. Hematol Oncol Stem Cell Ther 2010, 3:135-142.
16. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
17. Miller J.S., Cooley S., Parham P., Farag S.S., Verneris M.R., McQueen K.L., et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 2007, 109:5058-5061.
18. Suck G., Oei V.Y., Linn Y.C., Ho S.H., Chu S., Choong A., et al. Interleukin-15 supports generation of highly potent clinical-grade natural killer cells in long-term cultures for targeting hematological malignancies. Exp Hematol 2011, 39:904-914.
19. Niam M., Linn Y.C., Fook Chong S., Lim T.J., Chu S., Choong A., et al. Clinical scale expansion of cytokine-induced killer cells is feasible from healthy donors and patients with acute and chronic myeloid leukemia at various stages of therapy. Exp Hematol 2011, 39:897-903e1.
20. Peggs K.S., Verfuerth S., Pizzey A., Khan N., Guiver M., Moss P.A., et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003, 362:1375-1377.
21. Hanley P.J., Shaffer D.R., Cruz C.R., Ku S., Tzou B., Liu H., et al. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Cytotherapy 2011, 13:976-986.
22. Otto WR, Wright NA. Mesenchymal stem cells: from experiment to clinic. Fibrogenesis Tissue Repair.4:20.
23. Ringden O., Uzunel M., Rasmusson I., Remberger M., Sundberg B., Lonnies H., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81:1390-1397.
24. Prasad V.K., Lucas K.G., Kleiner G.I., Talano J.A., Jacobsohn D., Broadwater G., et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 2011, 17:534-541.
25. Madan R.A., Gulley J.L. Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer. Expert Rev Vaccines 2011, 10:141-150.
26. Madan R.A., Aragon-Ching J.B., Gulley J.L., Dahut W.L. From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. Expert Rev Vaccines 2011, 10:743-753.
27. Stroh D.A., Johnson A.J., Mont M.A. Surgical implants and technologies for cartilage repair and preservation of the knee. Expert Rev Med Devices 2011, 8:339-356.
28. Wollert K.C., Drexler H. Clinical applications of stem cells for the heart. Circ Res. 2005, 96:151-163.
29. Boyle A.J., Schulman S.P., Hare J.M., Oettgen P. Is stem cell therapy ready for patients? Stem cell therapy for cardiac repair. ready for the next step. Circulation 2006, 114:339-352.
30. Templin C., Krankel N., Luscher T.F., Landmesser U. Stem cells in cardiovascular regeneration from preservation of endogenous repair to future cardiovascular therapies. Curr Pharm Des 2011, 17:3280-3294.
31. Volarevic V., Ljujic B., Stojkovic P., Lukic A., Arsenijevic N., Stojkovic M. Human stem cell research and regenerative medicine-present and future. Br Med Bull 2011, 99:155-168.
32. Jung Y., Bauer G., Nolta J.A. Induced pluripotent stem cell-derived mesenchymal stem cells: progress toward safe clinical products. Stem Cells 2011 Sep 2, 2011. 10.1002/stem.727.
33. Bretzner F., Gilbert F., Baylis F., Brownstone R.M. Target populations for first-in-human embryonic stem cell research in spinal cord injury. Cell Stem Cell.8 2011, 468-475.
34. Stadtfeld M., Hochedlinger K. Induced pluripotency: history, mechanisms, and applications. Genes Dev 2011, 24:2239-2263.
35. Gore A., Li Z., Fung H.L., Young J.E., Agarwal S., Antosiewicz-Bourget J., et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011, 471:63-67.
36. Hussein S.M., Batada N.N., Vuoristo S., Ching R.W., Autio R., Narva E., et al. Copy number variation and selection during reprogramming to pluripotency. Nature 2011, 471:58-62.
37. Lister R., Pelizzola M., Kida Y.S., Hawkins R.D., Nery J.R., Hon G., et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011, 471:68-73.
38. Pera M.F. Stem cells: the dark side of induced pluripotency. Nature 2011, 471:46-47.